Highlights include: a memorandum of
understanding with Memorial Sloan Kettering Cancer Center and a
novel new partnership with Boundless Bio, a next-generation
precision oncology company
SOPHiA GENETICS' next-generation solution
CarePath, fueled by current real world observational data, was
previewed for attendees
BOSTON and GENEVA, Sept. 21,
2022 /PRNewswire/ -- SOPHiA GENETICS (Nasdaq:
SOPH), a cloud-native software company in the healthcare space,
hosted its first-ever Investor Day on Tuesday, September 20, 2022, in New York City.
The event, hosted by the CEO and Co-Founder Dr. Jurgi Camblong
and members of the executive leadership team, provided a roadmap of
the Company's long-term vision and highlighted new commercial
opportunities and partnerships. One takeaway from the event was
SOPHiA GENETICS' acceleration into the Biopharma space, which opens
the door for new opportunities for market growth. The audience also
heard how the Company's strategic business model allows for it to
continue to provide robust depth in the clinical space.
"A key theme throughout the day was how we innovate; how SOPHiA
GENETICS, from its inception, has identified opportunities in the
healthcare industry for innovation and acceleration of data sharing
to advance medicine, research and patient care," said Jurgi
Camblong, CEO and Co-Founder, SOPHiA
GENETICS. "Our vision is made possible by the strong
foundation our company has been built on, as well as the strategic
relationships we have formed to further our mission of
democratizing data-driven medicine."
New Collaboration with One of the
Top-Ranked Cancer Centers in the United
States
SOPHiA GENETICS recently announced a memorandum of understanding
to enter into a collaboration with Memorial Sloan Kettering
Cancer Center ("MSK"). Once executed, the collaboration
agreements will blend the power of SOPHiA GENETICS' large, global
network and deep expertise in predictive algorithms with MSK's
clinical expertise in cancer genomics. The collaboration agreements
will also allow SOPHiA GENETICS' global network of healthcare
providers access to MSK's proprietary tumor sequencing tests such
as MSK-IMPACT®, for analyzing tumors. Additionally, the
collaboration agreements will combine MSK's rich precision oncology
data with the SOPHiA CarePath™ module to enable the
acceleration of actionable insights from data to improve patient
outcomes.
"Our vision is to expand access to world-class data, including
to our current network, which contributes to the collective
intelligence of the SOPHiA GENETICS platform," said Philippe Menu,
M.D.-Ph.D., Chief Medical Officer, SOPHiA
GENETICS.
Enabling Biotech Developing Novel
Cancer Therapies Targeting Oncogene Amplification
SOPHiA GENETICS announced a partnership with Boundless Bio, a
next-generation precision oncology company developing innovative
therapeutics directed against extrachromosomal DNA (ecDNA) in
oncogene amplified cancers.
It has been well established that patients with oncogene
amplification generally do not benefit from standard of care cancer
treatments, and unlike other forms of oncogenic gene alterations,
oncogene amplification frequently occurs on ecDNA. ecDNA are
circular units of nuclear DNA that are distinct from normal
chromosomes and are the primary site for high copy number
amplification in cancer. Boundless Bio is developing the first
ecDNA-directed therapies (ecDTx) along with a precision diagnostic
method called ECHO (ecDNA Harboring Oncogenes) to detect ecDNA from
a patient's routine tumor sequencing data.
The partnership between Boundless Bio and SOPHiA GENETICS will
further develop ECHO for use in ecDTx clinical trials.
SOPHiA GENETICS' unique ability to harmonize data derived from
diverse genomic instruments and deploy as a robust, standardized
solution enables a new model for clinical trial testing. This
decentralized, global genomic solution combined with Boundless
Bio's ecDTx drug development capabilities aims to unlock value by
breaking the barriers inherent to the traditional central lab
approach; optimizing patient selection and clinical trial design;
and enabling a global collective network of major hospitals and
academic centers to effectively deliver new treatment options to
patients with oncogene amplified cancers.
"We are pleased to partner with SOPHiA GENETICS for the
development of Boundless Bio's ecDNA detection algorithm, ECHO,
into a clinical trial device" said Peter
Krein, Ph.D., Vice President of Precision Medicine at
Boundless Bio. "The ability to identify patients with ecDNA driven
tumors is critical to our mission in addressing this area of high
unmet medical need. SOPHiA GENETICS' unique expertise in developing
cloud based IVD NGS software algorithms makes them an ideal partner
to develop ECHO into an investigational device."
DEEP-Lung-IV Multimodal Clinical
Study Fuels New SOPHiA Carepath Platform
In late 2021, SOPHiA GENETICS launched a DEEP-Lung-IV Multimodal
Clinical Study with the goal of aggregating real-world
multimodal (genomic, clinical, biological and radiomic) data for
patients with metastatic non-small cell lung cancer. The study has
garnered interest from top-tier centers globally, with a strong
patient recruitment trend; to-date, nearly 900 patients across 23
sites have been enrolled in the study. As patients have been
followed along the patient journey, data sets have been collected
and analyzed by SOPHiA GENETICS' machine learning algorithm to
predict how the patients will respond to immunotherapy and why.
These robust and growing patient data will inform SOPHiA
GENETICS' artificial intelligence and machine learning that will
fuel the forthcoming SOPHiA CarePath™ module, a new product
that will be launched on the SOPHiA DDM™ Platform and aims to be
the vehicle healthcare practitioners can use to leverage the
real-world, real-time insights obtained from this study. The SOPHiA
CarePath™ module will provide the following benefits:
- Visualizing data form a single patient in a holistic manner
(genomic, clinical, biological and radiomic)
- Allow providers to cohort patients in the context of similar
patients from other institutions
Alongside these announcements, a full recording of the event is
available on the Investor Relations page of the company's
website.
About SOPHiA GENETICS
SOPHiA GENETICS (Nasdaq: SOPH) is a software company dedicated
to establishing the practice of data-driven medicine as the
standard of care and for life sciences research. It is the creator
of the SOPHiA DDM™ Platform, a cloud-native platform capable of
analyzing data and generating insights from complex multimodal data
sets and different diagnostic modalities. The SOPHiA DDM™ Platform
and related solutions, products and services are currently used by
a broad network of hospital, laboratory, and biopharma institutions
globally. For more information, visit SOPHiAGENETICS.COM, or
connect on Twitter, LinkedIn, Facebook,
and Instagram. Where others see data, we see
answers
SOPHiA GENETICS products are for Research Use Only and not
for use in diagnostic procedures, unless specified otherwise. The
information in this press release is about products that may or may
not be available in different countries and, if applicable, may or
may not have received approval or market clearance by a
governmental regulatory body for different indications for use.
Please contact support@sophiagenetics.com to
obtain the appropriate product information for your country of
residence.
SOPHiA GENETICS Forward-Looking
Statements:
This press release contains statements that constitute
forward-looking statements. All statements other than statements of
historical facts contained in this press release, including
statements regarding our future results of operations and financial
position, business strategy, products and technology, as well as
plans and objectives of management for future operations, are
forward-looking statements. Forward-looking statements are based on
our management's beliefs and assumptions and on information
currently available to our management. Such statements are subject
to risks and uncertainties, and actual results may differ
materially from those expressed or implied in the forward-looking
statements due to various factors, including those described in our
filings with the U.S. Securities and Exchange Commission. No
assurance can be given that such future results will be achieved.
Such forward-looking statements contained in this press release
speak only as of the date hereof. We expressly disclaim any
obligation or undertaking to update these forward-looking
statements contained in this press release to reflect any change in
our expectations or any change in events, conditions, or
circumstances on which such statements are based, unless required
to do so by applicable law. No representations or warranties
(expressed or implied) are made about the accuracy of any such
forward-looking statements.
View original content to download
multimedia:https://www.prnewswire.com/news-releases/sophia-genetics-unveils-strategy-to-drive-health-care-innovations-at-inaugural-investor-day-event-301629400.html
SOURCE SOPHiA GENETICS